Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.4455 USD | -2.00% | -2.07% | -95.96% |
24/05 | Allarity Therapeutics, Inc. Concludes Its Phase 2 Clinical Trial | CI |
14/05 | Allarity Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Sales 2024 * | - | Sales 2025 * | - | Capitalization | 7.84M 655M |
---|---|---|---|---|---|
Net income 2024 * | -16M -1.34B | Net income 2025 * | -28M -2.34B | EV / Sales 2024 * | - |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-0.17
x | P/E ratio 2025 * |
-0.29
x | Employees | 6 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 100% |
Latest transcript on Allarity Therapeutics, Inc.
1 day | -2.00% | ||
1 week | -2.07% | ||
Current month | -27.68% | ||
1 month | -25.71% | ||
3 months | -93.65% | ||
6 months | -96.07% | ||
Current year | -95.96% |
Managers | Title | Age | Since |
---|---|---|---|
Thomas Jensen
FOU | Founder | 46 | 01/20/01 |
Joan Brown
DFI | Director of Finance/CFO | 71 | 21/21/21 |
Chief Tech/Sci/R&D Officer | 63 | 01/21/01 |
Members of the board | Title | Age | Since |
---|---|---|---|
Chairman | 56 | 01/22/01 | |
Thomas Jensen
FOU | Founder | 46 | 01/20/01 |
Joseph Vazzano
BRD | Director/Board Member | 40 | 01/23/01 |
Date | Price | Change | Volume |
---|---|---|---|
21/24/21 | 0.4455 | -2.00% | 4,794,971 |
20/24/20 | 0.4546 | +3.01% | 1,704,362 |
18/24/18 | 0.4413 | +0.02% | 2,731,940 |
17/24/17 | 0.4412 | -3.01% | 1,998,854 |
Delayed Quote Nasdaq, June 22, 2024 at 01:30 am IST
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-95.96% | 7.84M | |
+15.19% | 121B | |
+19.91% | 114B | |
-19.80% | 20.43B | |
-15.85% | 16.55B | |
-13.45% | 16.45B | |
-44.35% | 15.59B | |
+66.67% | 15.19B | |
+2.13% | 13.54B | |
+119.39% | 10.96B |
- Stock Market
- Equities
- ALLR Stock